GleamWall
中文EN

RACC Research Alliance Corp III

Pharmaceutical Preparations · Nasdaq · SEC CIK 2118032 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA—
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets8.7%
Debt / equity—
Current ratio0.11x
Interest coverage—

Cash quality & payout

Operating cash flow / net income—
Accruals ratio—
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-30
Income statement
Revenue——
SG&A expense$977,793$184,418
Operating income-$977,793-$184,418
Net income-$1.95M$54,050
EPS (diluted)——
Balance sheet
Cash & equivalents$183,405$832,812
Current assets$312,054$961,461
Total assets$78.90M$76.31M
Current liabilities$2.91M$55,587
Total liabilities$6.85M$2.31M
Shareholders' equity-$3.90M-$1.24M
Cash flow statement
Operating cash flow——

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.